Serum Gamma-Glutamyl-Transferase Independently Predicts Outcome After Transarterial Chemoembolization of Hepatocellular Carcinoma: External Validation

2011 ◽  
Vol 35 (5) ◽  
pp. 1102-1108 ◽  
Author(s):  
Boris Guiu ◽  
Frédéric Deschamps ◽  
Mathieu Boulin ◽  
Valérie Boige ◽  
David Malka ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Chemoembolization ◽  
External Validation ◽  
Gamma Glutamyl Transferase ◽  
Gamma Glutamyl ◽  
Glutamyl Transferase

scholarly journals Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Qiao Ke ◽  
Fu Xiang ◽  
Chunhong Xiao ◽  
Qizhen Huang ◽  
Xiaolong Liu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Factor ◽  
Transarterial Chemoembolization ◽  
Radical Resection ◽  
Gamma Glutamyl Transferase ◽  
Clinical Value ◽  
Gamma Glutamyl ◽  
Preoperative Serum ◽  
Before And After ◽  
Glutamyl Transferase

Abstract Background Preoperative serum gamma-glutamyl transferase (γ-GT) levels is significantly related to the prognosis of hepatocellular carcinoma (HCC), but its clinical value in the management of postoperative adjuvant transarterial chemoembolization (PA-TACE) has rarely been explored. This study aimed to investigate whether γ-GT levels could be taken as a biomarker to guide the management of PA-TACE in resectable HCC. Methods HCC patients receiving radical resection were identified through the primary liver cancer big data (PLCBD) from December 2012 to December 2015. Prognostic factors of overall survival (OS) and disease-free survival (DFS) were identified by univariate and multivariate cox analyses, and subgroup analysis was conducted between PA-TACE group and non-TACE stratified by γ-GT levels before and after 1:1 propensity score matching (PSM). Results γ-GT level was found to be an independent risk factor of OS and DFS in 1847 HCC patients receiving radical resection (both P < 0.05), and patients with elevated γ-GT(> 54.0 U/L) have a shortened median OS and DFS, compared with those with normal γ-GT (both P < 0.001). In the subgroup of patients with normal γ-GT, there were no significant differences between groups of PA-TACE and non-TACE in terms of median OS and DFS before and after PSM (all P > 0.05), and PA-TACE was not a significant prognostic factor of both OS and DFS before and after PSM (all P > 0.05). In the subgroup of patients with elevated γ-GT, significant differences were found between groups of PA-TACE and non-TACE in terms of median OS and DFS before and after PSM (all P < 0.05), and PA-TACE was an independent prognostic factor of both OS and DFS (all P < 0.05). Conclusion Currently, we concluded that patients with more advanced HCC also have more elevated γ-GT, and these patients with elevated γ-GT would be benefited more from PA-TACE after radical resection.

scholarly journals Can gamma-glutamyl transferase levels contribute to a better prognosis for patients with hepatocellular carcinoma?

2014 ◽  
Vol 8 (3) ◽  
pp. 134-138 ◽  
Author(s):  
Zhigang Wang ◽  
Peipei Song ◽  
Jufeng Xia ◽  
Yoshinori Inagaki ◽  
Wei Tang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Gamma Glutamyl Transferase ◽  
Gamma Glutamyl ◽  
Glutamyl Transferase

CURRENT UPDATES ON DIAGNOSTIC BIOMARKERS OF HEPATOCELLULAR CARCINOMA

INDIAN DRUGS ◽  
2019 ◽  
Vol 56 (06) ◽  
pp. 7-23
Author(s):  
N Hasan ◽  
◽  
M Mukim ◽  
P Sharma ◽  
U. S. Baghel ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Growth Factor ◽  
Clinical Aspects ◽  
Cytokeratin 19 ◽  
Gamma Glutamyl Transferase ◽  
Urokinase Plasminogen Activator Receptor ◽  
Diagnostic Biomarkers ◽  
Gamma Glutamyl ◽  
Micro Rnas ◽  
Glutamyl Transferase

Hepatocellular carcinoma (HCC) is a liver malignancy, which is a cause of several deaths related to cancer worldwide. In early stages, curative treatment such as surgical resection, liver transplant and local ablation can improve the patient’s survival. However, the disease is often diagnosed in an advanced stage; moreover, some available therapies are restricted to palliative care and local treatment. Early diagnosis of HCC and adequate therapy are crucial to increasing survival as well as to improve the patient’s quality of life. Therefore, many researchers have been investigating biomarkers such as alpha-fetoprotein (AFP), glypican-3 (GPC3), des-γ-carboxyprothrombin, gamma-glutamyl transferase (GGT), serum α-L-fucosidase (AFU), carbonyl reductase 2, golgi phosphoprotein 2, transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor (VEGF), tumor- specific growth factor (TSGF), epidermal growth factor receptor family (EGFR), hepatocyte growth factor/scatter factor, fibroblast growth factor (FGF), circulating nucleic acids (mRNAs), gamma-glutamyl transferase mRNA (GGT mRNA), insulin-like growth factor II (IGF-II) mRNA, albumin mRNA, circulating micro RNAs, heat shock protein (HSP), Golgi protein 73 (GP73), squamous cell carcinoma antigen (SCCA), tumor-associated glycoprotein 72 (TAG-72), zinc-α2-glycoprotein (ZAG), cytokeratin 19, osteopontin, midkine (MDK), gankyrin, annexin A2, soluble urokinase plasminogen activator receptor (suPAR), AXL, thioredoxins (TRXs), cluster of differentiation 147 (CD147) and microRNAs, which can regulate important pathways in carcinogensis, tumor angiogenesis and progression. So, they can be considered as possible markers of progression in HCC and therapeutic targets for this type of cancer. In this review, we discuss the recent advances related to diagnostic biomarkers, clinical aspects and outcome in hepatocellular carcinoma.

Sign in / Sign up

Export Citation Format

Share Document